吸入型胰岛素可能导致肺癌
Pfizer warns of lung cancer link with inhaled insulinUS drugmakers Pfizer Inc and Nektar Therapeutics on Wednesday warned of cases of lung cancer in clinical trials of their inhaled insulin Exubera.
美国辉瑞制药公司 和Nektar Therapeutics公司警告他们的喷吸胰岛素 Exubera可能导致肺癌
The findings led Nektar to announce it was abandoning its search for a new marketing partner for the troubled drug, effectively signaling Exubera's demise after entering the market in January 2006.
这个结论导致Nekta宣布放弃为这个麻烦的药物寻找新的市场合作伙伴，这意味从2006年进入市场以后， Exubera已完全失败。
Pfizer, the world's largest pharmaceutical company, announced last October it stopped marketing Exubera, saying it did not meet customer needs or the financial expectations of the company.
美国辉瑞，国际制药业的巨头，去年10月辉瑞宣布停止销售Exubera,说Exubera或者不能被病人所接受或不能为公司创造足够的经济利益。
The rise in lung cancer apparently linked to Exubera led Pfizer to update the medication's warning label to include information \"about lung cancer cases observed in patients who used Exubera,\" the company reported in a statement.
公司宣称，肺癌的发病率上升明显与 Exubera相关，公司已更新了药物警告的标签包括：“使用Exubera的患者发现了肺癌病例。”
It said that over the course of the clinical trial, six out of 4,740 Exubera-treated patients developed lung cancer, versus one of the 4,292 patients not treated with Exubera.
据说在Exubera临床试验过程中，在4740 Exubera治疗的患者中，有6人出现了肺癌，而对照组4292人中只有1人。
An additional case of lung cancer in an Exubera-treated patient was discovered after the drug's debut on the market following its approval by the US Food and Drug Administration.
当FDA Exubera开始进入市场后，另外一例肺癌也被发现，。
The updated label states that all patients who developed lung cancer had a prior history of cigarette smoking, and that there were \"too few cases to determine whether the development of lung cancer is related to the use of Exubera.\"
最新的药物标签声明，所有的得肺癌患者都有吸烟史，所以肺癌是否是由于使用Exubera引起，目前病例数太少。
\"Some patients continue to take Exubera, including those enrolled in extended transition programs or clinical trials,\" Pfizer chief medical officer Joe Feczko said in the statement.
辉瑞医疗主管Joe Feczko在一个声明中说：“有一些病人仍在继续使用Exubera，包括进入过渡计划试验延长期和临床试验的患者。”
\"We are working closely with patients and their physicians to ensure the continued orderly transition from Exubera to alternative therapies,\" he added.
他补充说：”我们与这些患者和他们的医生密切联系，保证他们从持续的 Exubera过渡到其他治疗。“
Nektar announced it was stopping all spending on the drug, including research and marketing.
Nektar 宣布不再在这个药物上投资，包括研究和销售。
\"The concern over this new data analysis from ongoing clinical trials has resulted in the termination of all negotiations with potential partners,\" said Nektar president Howard Robin on the company's website.
Nektar 总裁Howard Robin 在公司网站上说：“由于对这次进行中的临床试验的分析结果的关注，导致与所有潜在的合作伙伴的协商不可能成功。”
Diabetes affects 230 million people worldwide, including 21 million in the United States, according to Pfizer. Exubera is a short-acting insulin breathed in through an inhaler that helps control high blood sugar in people with diabetes.
全世界约有230 百万人糖尿病患者，21 百万在美国。Exubera是通过呼吸吸入的速效胰岛素用于控制糖尿病患者的血糖。
不知道对MannKind有何影响，吸入胰岛素的最后一家
页:
[1]